Mucocutaneous leishmaniasis complicating systemic lupus erythematosus and responding to high dose amphotericin B.
2021
A L Matos, and
C Figueiredo, and
F Alves, and
N Pereira, and
M Gonçalo
Dermatology Department, Coimbra University Hospital Centre, Coimbra, Portugal.
UI
MeSH Term
Description
Entries
D007897
Leishmaniasis, Mucocutaneous
A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.